Kineta’s expertise in drug discovery and early-stage development presents opportunities for established companies or laboratories seeking to out-license inactive programs with demonstrated scientific promise. We currently seek to add to our development portfolio early-stage compounds with promising applications against viral and autoimmune diseases.

Kineta is seeking development collaborations for our promising discovery stage programs. We also are actively evaluating promising in-licensing opportunities where there is common interest in advancing programs through non-clinical to proof of concept stage. For more information on our corporate initiatives, please contact Bill Cadwallader at bcadwallader@kinetabio.com or by calling 206-518-5566.

COLLABORATORS:
Cubist Pharmaceuticals
Kineta is working with Cubist pharmaceuticals on completing
the preclinical / scientific studies to enable CB-183872 a novel Hepatitis C biologic to enter clinical trials. Cubist Pharmaceuticals (NASDAQ: CBST) is a biopharmaceutical company focused on developing and commercializing anti-infective therapies for the acute care environment.

National Institutes of Health
The National Institutes of Health (NIH) is a partner with Kineta on the RIG-I program. NIH has committed substantial development funding under the Small Business Innovation Research program, to design a structure-guided approach to identify small-molecule agonists of the cellular RIG-I pathway. This project is supported by Award Number R43AI081335 from the National Institute of Allergy and Infectious Diseases.